铁质积聚服用地拉罗司治疗的效果

Deferasirox (deferasirox) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron chelator approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. The application of iron chelators has greatly reduced the mortality and improved the quality of life of patients with long-term blood transfusions, and its clinical application has been receiving widespread attention and attention.

A multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of deferasirox in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS).

The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of deferasirox is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d.

A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33).

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal.

According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS.

The above are the effects of taking iron accumulation treatment. For more information about deferasirox, please contact Medical Companion Travel for details.

Recommended related hot articles: /newsDetail/82868.html